BioSpace News Archive

Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster and oral presentations at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT) in Washington, D.C.

Meeting Highlights Include New Phase 3 Data for EPIDIOLEX in Tuberous Sclerosis Complex and Award-Winning Virtual Reality Experience

Company seeks swine producers to run commercial trials

Topline results from NASH Phase II study expected Q1 2020

In this role, Kenny will serve on the Company’s Executive Leadership team and be responsible for leading the global spinal implants, motion preservation, bone growth therapies, and biologics businesses.

Event to Highlight Preliminary Data from the Phase 1 Trial of RP-L102 “Process B” for Fanconi Anemia and from the Phase 1 Trial of RP-L201 for Leukocyte Adhesion Deficiency

Encompass Health Corp. (NYSE: EHC) today announced it will participate in the 38th Annual J.P. Morgan Healthcare Conference being held Jan. 13-16, 2020, in San Francisco, California

Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), the market leader in Transcranial Magnetic Stimulation (“TMS”) in the United States, is pleased to announce that Bill Leonard, Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York, NY on December 5, 2019 at 11:30 a.m. Eastern Time.

Innovative Cellular Therapeutics (ICT), a biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors, today announced the appointment of Morten Marott, who joined ICT as Chief Financial Officer in July 2019

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced it completed enrollment of the pivotal cohort in its Phase 3 clinical trial evaluating setmelanotide for the treatment of insatiable hunger and severe obesity in individuals living with Bardet-Biedl syndrome (BBS) or Alström syndrome.